PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
This is PART A of a 2-part, 6-week, double-blind, dose-optimization, parallel-group study in children and adolescents (ages 6-17 years) with ADHD with and without CNVs in specific genes implicated in glutamatergic signaling and neuronal activity. Parts A will include subjects determined to have a specific gene mutations implicated in glutamatergic signaling and neuronal connectivity.
Epistemonikos ID: e6b20d306a24bc8872de08a80ce91e53cfa77fa9
First added on: May 21, 2024